Quanterix’ Simoa Technology Powers Record Number of Presentations and Poster Sessions at ECTRIMS 2018
International multiple sclerosis conference features 35 new studies using Simoa technology demonstrating potential of Neurofilament light chain (NfL) as a reliable and sensitive disease biomarker
“Like many neurodegenerative conditions, Multiple Sclerosis is difficult
to diagnose objectively and disease progression is determined primarily
by imaging and symptoms reported,” said
MS is among the most prevalent neurodegenerative conditions affecting
individuals between the ages of 20 and 50 years old. The National
Sessions featuring Quanterix’ Simoa technology at ECTRIMS 2018 will explore blood-based NfL’s correlation with MS and assess the biomarker’s reliability compared to traditional cerebral spinal fluid (CSF) alternatives in both adult and pediatric MS. This year’s program boasts a 250 percent increase in Simoa-powered research for the study of NfL in MS compared to last year’s program and a more than 400 percent increase compared to the 2016 conference. Research spanning these three consecutive years, which totals nearly 50 peer-reviewed studies, substantiates Simoa as a critical technology for the detection and analysis of NfL in blood. Presentations and posters at this year’s ECTRIMS add to a growing body of research supporting Simoa’s potential to detect and quantify NfL for a variety of neurodegenerative conditions.
To learn more about
To learn more about Quanterix’ NfL assay, click here.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the
Lindsay Poole, 617-502-4300